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AbstrAct
ObjeCtive
To investigate the impact of smoking and smoking 
cessation on cardiovascular mortality, acute coronary 
events, and stroke events in people aged 60 and older, 
and to calculate and report risk advancement periods 
for cardiovascular mortality in addition to traditional 
epidemiological relative risk measures.
Design
Individual participant meta-analysis using data from 
25 cohorts participating in the CHANCES consortium. 
Data were harmonised, analysed separately employing 
Cox proportional hazard regression models, and 
combined by meta-analysis.
Results
Overall, 503 905 participants aged 60 and older were 
included in this study, of whom 37 952 died from 
cardiovascular disease. Random effects meta-analysis 
of the association of smoking status with 
cardiovascular mortality yielded a summary hazard 
ratio of 2.07 (95% CI 1.82 to 2.36) for current smokers 
and 1.37 (1.25 to 1.49) for former smokers compared 
with never smokers. Corresponding summary 
estimates for risk advancement periods were 5.50 
years (4.25 to 6.75) for current smokers and 2.16 years 
(1.38 to 2.39) for former smokers. The excess risk in 
smokers increased with cigarette consumption in a 
dose-response manner, and decreased continuously 
with time since smoking cessation in former smokers. 
Relative risk estimates for acute coronary events and 
for stroke events were somewhat lower than for 
cardiovascular mortality, but patterns were similar.
COnClusiOns
Our study corroborates and expands evidence from 
previous studies in showing that smoking is a strong 
independent risk factor of cardiovascular events and 
mortality even at older age, advancing cardiovascular 
mortality by more than five years, and demonstrating 
that smoking cessation in these age groups is still 
beneficial in reducing the excess risk.
background
In 1964, the first of a series of the US Surgeon General’s 
reports on the health consequences of smoking con-
cluded that male smokers had a higher death rate from 
coronary heart disease than non-smoking males, but 
evidence was yet not sufficient to conclude a causal 
relation.1 In the 50 years since the publication of this 
landmark report, ever stronger epidemiological evi-
dence for a causal link between tobacco smoking and 
cardiovascular diseases and mortality has accrued from 
a multitude of prospective cohort studies.2 3 During the 
same decades cardiovascular mortality rates have been 
decreasing in developed countries, as have rates of cig-
arette consumption, but cardiovascular disease 
remains a leading cause of death.4
The incidence of cardiovascular disease increases 
with age and most events occur in older adults.5 Given 
current demographic trends, prevention in older adults 
through risk factor management is of crucial impor-
tance to reduce the burden of cardiovascular disease. 
But despite being one of the major modifiable risk fac-
tors, few prospective studies have specifically investi-
gated the effect of smoking6–12 and smoking cessation7 8 
on cardiovascular outcomes at advanced age. These 
studies suggest that even in later life, smoking is a risk 
factor for cardiovascular deaths and disease, and that 
smoking cessation could still be beneficial.
Communicating the risks of smoking and the benefits 
of quitting to smokers could be an effective means to 
promote cessation. While relative risks might be espe-
cially difficult to grasp for lay people, risk advancement 
WhAt is AlreAdy knoWn on this topic
Generally, smoking is a major modifiable risk factor for disease and death, and 
smoking cessation is beneficial in reducing smoking related risks
However, even though most cardiovascular events occur in older adults, this age 
group has been understudied when it comes to the cardiovascular risks of smoking 
and the potential benefits of smoking cessation on cardiovascular health
WhAt this study Adds
Using data from a large consortium of cohorts from all over Europe and the United 
States, we corroborated and expanded evidence from previous studies to show that 
smoking is a strong independent risk factor for cardiovascular events and mortality 
among older adults. We demonstrated that even at older ages, smoking cessation 
is beneficial in reducing the cardiovascular excess risk caused by smoking
Hence, given the increasing numbers of older people and the higher incidence of 
cardiovascular events and mortality at older age, there is tremendous potential for 
smoking and cardiovascular disease prevention in this group of people
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periods have been proposed to be of particular use in 
risk communication.13 14 The risk advancement period 
(RAP) gives the average time by which the occurrence of 
an event (such as disease incidence or death) due to a 
risk factor is advanced in exposed people compared 
with unexposed people.15
With this work, we sought to provide evidence of the 
impact of smoking and smoking cessation on cardio-
vascular outcomes in people aged 60 and older, in a 
meta-analysis of individual participant data from 
cohort studies from Europe and the United States par-
ticipating in the CHANCES consortium (Consortium on 
Health and Ageing: Network of Cohorts in Europe and 
the United States). In addition to traditional epidemio-
logical relative risk measures, we also calculated and 
report the risk advancement period for cardiovascular 
mortality. 
Methods
study design and participants
This study was conducted within the CHANCES consor-
tium (http://www.chancesfp7.eu/).16 This collaborative 
project aims at combining and integrating data from 
cohort studies conducted in Europe and North America 
in order to study major age related chronic conditions 
and to produce evidence on health determinants in 
older adults. The consortium includes 15 population 
based cohort studies, including several multicentre 
studies, with participants from 24 countries. The data 
from these cohort studies were combined by harmonis-
ing variables of interest according to pre-agreed and 
consented harmonisation rules.
For this study, we used data from 10 cohort studies 
and cohort consortia of the CHANCES consortium and 
additionally from two cohort studies with open data 
access (ELSA, NHANES III), adding up to 25 different 
cohorts with participants from 23 countries (see table 1 
for an overview, with detailed descriptions of these 
cohort studies provided in the appendix). Because there 
have been only a few studies on the cardiovascular risks 
of smoking in older age, we focused our study on older 
adults and included only people aged 60 and older.
All CHANCES cohort studies are conducted in accor-
dance with the Declaration of Helsinki. For each study, 
investigators satisfied the local requirements for ethical 
research, including obtaining informed consent from 
participants.
Outcomes
Three cardiovascular outcomes were examined in this 
study. As primary outcome, cardiovascular deaths were 
defined as fatal cardiovascular events according to 
cause of death (that is, ICD-8, codes 390–458; ICD-9, 
codes 390–459; ICD-10, codes I00-I99). Cause of death 
was obtained from death registers or from death certifi-
cates. The only exception was the SHARE cohort, for 
which cause of death was ascertained through an “end 
of life interview” with a household member or another 
close contact of the deceased person. Secondary out-
comes were incidence of acute coronary events and 
stroke. For the incidence analyses people were excluded 
who had a history of acute coronary events or stroke 
before inclusion in the study. Acute coronary events 
comprised confirmed fatal and non-fatal coronary 
events including acute myocardial infarction, unstable 
angina pectoris or coronary death according to perti-
nent definitions used in the respective cohort studies 
(such as WHO definition17 or WHO MONICA criteria18). 
Stroke events comprised fatal or non-fatal acute events 
that fulfilled the typical symptoms of stroke (that is, 
people presenting clinical signs and symptoms sugges-
tive of subarachnoid haemorrhage, intracerebral haem-
orrhage, or cerebral infarction). Both acute coronary 
and stroke events were identified through linkage to 
registries, contact with a physician, through follow-up 
questionnaires (self report), or interviews with close rel-
atives. If a case was identified through self report or 
interview with a relative, validation was achieved 
through contact with the participant’s physician, or by 
retrieving medical records, hospital discharge diagnoses, 
death certificates, or autopsy reports.
All included cohort studies provided data on cardio-
vascular deaths; however, non-fatal acute coronary and 
stroke events were not available for MORGAM SHIP 
Greifswald, NHANES, NIH-AARP, SENECA, or SHARE.
exposure variables
All included cohort studies collected data on current 
smoking status at baseline using interviews or self 
administered questionnaires, and most studies also col-
lected data on smoking intensity and smoking cessa-
tion (see supplementary table 1 for an overview of 
availability of variables). Current smoking status 
describes the status of never, former, or current smok-
ing of tobacco products at the time of the baseline inter-
view. Current smoking was regular or daily smoking, 
according to the cohort study’s definition. Never smok-
ing was either defined as never having smoked daily or 
regularly or as not having smoked more than 100 ciga-
rettes over a lifetime. Current intensity of smoking was 
assessed as the average consumption of cigarettes per 
day. Smokers with available information on cigarette 
smoking intensity were categorised into the following 
categories: smoking <10 cigarettes per day, 10–19 ciga-
rettes per day, ≥20 cigarettes per day. Former smokers 
were asked for age or date of smoking cessation and, 
according to the time since smoking cessation at base-
line, were categorised into the following categories: 
stopped smoking <5 years ago, 5–9 years ago, 10–19 
years ago, ≥20 years ago.
Covariates
Covariates comprised sex, age, education, alcohol con-
sumption, body mass index (BMI), physical activity, 
history of diabetes, total cholesterol, and systolic blood 
pressure. All of these variables were measured at base-
line. Education was categorised into low, moderate, 
and high, which was either based on the highest level of 
education (low: primary education or less; moderate: 
more than primary but less than college or university 
education; high: college or university education), or on 
the number of years in full time education which was 
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then translated into categories (low: <10 years of educa-
tion; moderate: 10 or 11 years; high: ≥12 years). Alcohol 
consumption was assessed as average daily alcohol 
intake per day (g) and categorised into three categories 
based on sex specific cut-offs: non-drinker (0 g of alco-
hol per day), moderate drinker (women: ≥0 g to <10 g 
per day; men: ≥0 g to <20 g per day), and heavy drinker 
(women: ≥10 g per day, men: ≥20 g per day).19 For 
SHARE three categories were defined on the basis of the 
usual drinking pattern according to the number of days 
per week on which alcohol was drunk (non-drinker: self 
reported non-drinking; moderate drinker: drinking on 
≤2 days per week; heavy drinker: drinking on ≥3 days 
per week). BMI was computed as body weight in 
 kilograms divided by squared body height in metres, 
with weight and height having been assessed either 
through self report or through measurement. BMI was 
categorised into normal weight (BMI of ≤25 kg/m2), 
overweight (25 to <30 kg/m2), and obese (≥30 kg/m2). 
Physical activity was coded as a binary variable indicat-
ing whether participants engage in vigorous physical 
activity at least once per week. History of diabetes was 
a binary variable that was based either on self report of 
participants, on validated information from their phy-
sicians, diabetes registers or medical records, or on 
results of blood measurements (such as 2 hour plasma 
glucose ≥200 mg/ml in an oral glucose tolerance test, 
HbA1c ≥6.5%, or fasting plasma glucose ≥126 mg/dl). 
Total cholesterol (mmol/l) was measured from serum or 
plasma; if plasma was used, values were converted into 
serum values. Systolic blood pressure (mm Hg) was 
either measured in a baseline examination, or obtained 
from other sources of information such as medical 
records or through participants’ physicians. Both total 
cholesterol and systolic blood pressure were used as 
continuous variables.
statistical analyses
For the multivariable analyses, multiple Cox propor-
tional hazards regression models were employed to 
estimate hazard ratios and 95% confidence intervals for 
the associations of the smoking related predictors with 
the three different cardiovascular outcomes. This was 
done separately for each cohort by using uniform anal-
ysis scripts. If a cohort consisted of sub-cohorts from 
different survey periods (as in the case of all MORGAM 
cohorts except SHIP Greifswald) or was a multicentre 
study (SHARE, SENECA), then a stratified Cox model 
was employed allowing the baseline hazard to vary 
between strata—that is, across sub-cohorts or centres, 
respectively. The proportional hazards assumption was 
assessed graphically for each cohort. Three models 
with different sets of adjustments were fitted. The sim-
ple model was adjusted for sex and age. The main 
model was additionally adjusted for education, alcohol 
consumption, BMI, and physical activity. However, for 
a few cohorts, not all variables were available or could 
not be harmonised according to the CHANCES variable 
harmonisation rules. In particular, harmonised 
 variables for alcohol consumption were not available 
for MORGAM Northern Sweden and for NHANES t
ab
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(in NHANES information on alcohol consumption was 
only collected in the subpopulation of those participat-
ing in the medical examination), and harmonised vari-
ables for physical activity were not available for the 
MORGAM cohorts and for EPIC-Elderly Sweden 
(see supplementary table 1 for an overview). In those 
cases, the main model was fitted without this particular 
variable. An additional model was further adjusted for 
history of diabetes, total cholesterol, and systolic blood 
pressure in addition to the covariates included in the 
main model. The rationale for this analysis was to 
explore if and to what extent the observed associations 
might be mediated by diseases for which smoking is a 
well known risk factor.2 However, these variables were 
not available for all cohorts.
We used the results of the multivariable Cox models 
to calculate risk advancement periods and their 95% 
confidence intervals, which are reported for the primary 
outcome in addition to hazard ratios. Risk advancement 
periods are calculated as the ratio of the regression 
coefficients of the respective predictor variable and age 
(see appendix for further details and formulas) and 
quantify by how many years cardiovascular mortality is 
advanced in exposed participants compared with the 
unexposed reference group (for example, current smok-
ers in comparison with never smokers).15 In a few cases, 
if the cohorts had only a very narrow age range that did 
not offer enough variation to compute reliable estimates 
of the regression coefficients for age, the resulting risk 
advancement periods would not be meaningful and 
were therefore not calculated.
After the estimation of hazard ratios and risk 
advancement periods for the single cohorts, meta-anal-
yses were applied in order to calculate summary hazard 
ratios and risk advancement periods estimates across 
cohorts. We computed both fixed effects models, and 
random effects models using the DerSimonian-Laird 
method.20 Owing to substantial heterogeneity across 
cohort results as assessed with I2 and Q statistics,21 
 random effects estimates are reported as the main 
results, since random effects models account for vari-
ability of effects across individual studies. We explored 
age and sex differences by subgroup analyses. Several 
sensitivity analyses (especially through exclusion of 
studies) were conducted to assess the robustness of the 
summary estimates. Dose-response relations were 
assessed by meta-analysis for dose-response data using 
the Greenland and Longnecker method22 and a random 
effects model as implemented in the SAS%metadose 
macro.23
All statistical tests were two sided, with an alpha 
level of 0.05. SAS v.9.3 was used for the descriptive sta-
tistics, the survival analyses, and the dose-response 
meta-analysis. R v.3.0.2 and the package ‘meta’24 were 
used to carry out the main individual participant 
meta-analyses.
results
In total, 503 905 participants aged 60 and older were 
included in this study, with 37 952 cardiovascular 
deaths recorded during follow-up (table 1). NIH-AARP 
was the largest study, contributing 366 919 participants 
and 25 769 cardiovascular deaths. The mean follow-up 
time was between approximately 8 and 13 years for 
most of the studies, with the noteworthy exception of 
SHARE with a substantially shorter mean follow-up of 
just 1.6 years. About half of the cohorts had substantial 
proportions of participants equal to or above the age of 
70 at baseline (for example, ELSA, NHANES, SHARE, 
Tromsø, Zutphen), while the other half consisted exclu-
sively or predominantly of adults below that age, 
including the biggest study NIH-AARP. Altogether, only 
13.4% of the sample (67 639) was 70 years or older, but 
22.8 of all deaths (8638) occurred in this age group . 
Two cohorts comprised only participants of one sex, 
SMC (only women) and Zutphen (only men). Overall, 
44% of the meta-analysed sample were female 
(221 678). Ninety four per cent (474 583) of all partici-
pants had reported their current smoking status. 
Among these, smoking prevalence varied widely, from 
8.9% in the SMC cohort to 37.1% in MORGAM Glostrup. 
Overall, 40.2% (190 688) of participants were self 
reported never smokers, 47.4% (225 158) were former 
smokers, and 12.4% (58 737) were current smokers.
Meta-analysis of the association of smoking status 
with cardiovascular mortality yielded a summary haz-
ard of 2.07 (95% confidence interval 1.82 to 2.36) for cur-
rent smokers and of 1.37 (1.25 to 1.49) for former smokers 
compared with never smokers (fig 1). Corresponding 
summary estimates for risk advancement periods were 
5.50 (4.25 to 6.75) for current and 2.16 (1.38 to 2.39) for 
former smokers (fig 2). The excess risk in smokers 
increased with cigarette consumption; the highest haz-
ard ratio of 2.63 (2.28 to 3.04) and the corresponding risk 
advancement period estimate of 6.90 (5.59 to 8.20) were 
found in current smokers who smoked 20 or more ciga-
rettes per day (fig 3; supplementary figs 3 and 4). The 
trend of risk increase per 10 cigarettes was 1.40 (1.33 to 
1.47, P<0.001; details not shown). In former smokers, 
the smoking related cardiovascular mortality risk 
decreased continuously with time since smoking cessa-
tion with a hazard ratio for trend per 10 years of 0.85 
(0.82 to 0.89, P<0.001; details not shown). Participants 
who had stopped smoking less than 5 years before base-
line had a reduced hazard ratio for cardiovascular mor-
tality of 0.90 (0.81 to 1.00), which translated to a risk 
advancement period estimate of −0.82 (−1.72 to 0.07) 
compared with continuing smokers. Corresponding 
hazard ratios and risk advancement period estimates 
for participants having quit 5–9 years ago were 0.84 
(0.73 to 0.95) and −1.34 (−2.29 to −0.39), were 0.78 (0.71 to 
0.85) and −1.96 (−2.69 to −1.24) for those having quit 10 
to 19 years ago, and were 0.61 (0.54 to 0.69) and −3.94 
(−4.86 to −3.03) for those having quit 20 or more years 
ago (fig 3; supplementary figs 5 and 6). A similar pattern 
of decreasing excess risk was seen when the cardiovas-
cular mortality risk was modelled in reference to never 
smokers with a hazard ratio for trend of 0.82 per 10 
years (0.78 to 0.86, P<0.001; details not shown). Former 
smokers who had stopped smoking less than 5 years 
ago had a hazard ratio of 1.74 (1.51 to 2.01), which 
decreased in a dose- response manner with categories of 
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time since smoking, and those who had stopped smok-
ing 20 or more years ago only had a slightly increased 
hazard ratio of 1.15 (1.02 to 1.30). The risk advancement 
period estimates decreased accordingly with categories 
of time since smoking cessation from 3.75 (2.78 to 4.71) 
in former smokers who had quit less than 5 years ago to 
a merely insignificantly elevated risk advancement 
period of 0.79 (−0.12 to 1.69) in those who had quit 20 or 
more years ago (fig 3; supplementary figs 9 and 10).
Further sex and age stratified analyses of the associa-
tion of time since smoking cessation with cardiovascu-
lar mortality revealed quite consistent patterns across 
sex and age (fig 4; supplementary figs 7 and 8). Even 
though the dose-response relation of time since smok-
ing cessation with cardiovascular mortality seems 
somewhat weaker in those aged 70 and older than in 
those aged 60 to 69, we still observed a clear decline of 
the risk with time since smoking cessation even in the 
oldest age group.
Similar patterns to those for cardiovascular mortality 
were seen for the associations of smoking related pre-
dictors with acute coronary and stroke events, albeit 
somewhat weaker, particularly in the case of stroke 
events (fig 5; supplementary figs 11, 14, 15, 16, 19, 20). 
Hazard ratios for acute coronary events were 1.98 (1.75 
to 2.25) for current smokers and 1.18 (1.06 to 1.32) for for-
mer smokers. The respective hazard ratios for stroke 
were 1.58 (1.40 to 1.78) and 1.17 (1.07 to 1.26). For both 
acute coronary and stroke events, risks tended to 
increase with daily cigarette consumption in current 
smokers (hazard ratio for linear trend per 10 cigarettes 
were: 1.36 (1.28 to 1.45, P<0.001 for acute coronary 
events, and 1.25 (1.19 to 1.31), P<0.001 for stroke; details 
not shown), and to decrease with time since smoking 
cessation in former smokers (hazard ratios for linear 
trend per 10 years were: 0.83 (0.78 to 0.89), P<0.001 for 
acute coronary events, and 0.87 (0.84 to 0.91), P<0.001 
for stroke; details not shown).
Summary estimates from age and sex stratified analy-
ses for smoking status are reported in table 2 (see also 
supplementary figs 1, 2, 12, 13, 17, 18). Age and sex specific 
patterns were quite similar across outcomes. Risk esti-
mates were somewhat higher in women compared with 
men; this difference was most pronounced for the risk of 
acute coronary events in current smokers, which was 
2.26 (1.98 to 2.59) in women and 1.80 (1.51 to 2.15) in men. 
Hazard ratios also tended to be higher for 60 to 69 year 
old participants compared with those aged 70 or older. 
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Fig 1 | Meta-analysis of the association of current smoking status with cardiovascular mortality
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The greatest age difference was observed for the risk of 
cardiovascular mortality in current smokers, which was 
2.45 (2.22 to 2.69) in 60 to 69 year olds compared with 1.70 
(1.42 to 2.04) in those aged 70 or older.
Sensitivity analyses for meta-analyses excluding 
those studies for which physical activity or alcohol con-
sumption information was not available as covariates 
showed very similar results (deta not shown). Further 
analyses included additional adjustment for history of 
diabetes, blood pressure, and total cholesterol. How-
ever, adding these covariates did not change the sum-
mary estimates to any relevant extent (details not 
shown).
discussion
Principal findings
To our knowledge, the present work is currently the 
largest and most comprehensive study on the associa-
tion of smoking with cardiovascular disease and mor-
tality in older adults. We drew on harmonised and 
uniformly analysed data from a number of cohorts from 
Europe (covering eastern, northern, southern, western, 
and central Europe) and the US, and combined these 
studies by individual participant data meta-analyses. 
Our results show that in people aged 60 years and older, 
smoking strongly contributes to acute coronary events, 
stroke, and cardiovascular deaths. Smokers had two-
fold hazards of cardiovascular mortality compared with 
never smokers, which, in terms of risk advancement 
periods, advanced the risk of dying from cardiovascular 
disease by 5.5 years. The hazard of incident acute coro-
nary events for smokers was also twofold, and 1.5-fold 
for stroke events. Among smokers, the excess risk 
increased with higher levels of cigarette consumption. 
The increased excess risk among former smokers 
declined with time after smoking cessation in a dose-re-
sponse manner.
Comparison with other studies
Only a few previous prospective studies on the associa-
tion of smoking with cardiovascular outcomes included 
older adult populations,6–11 and even fewer focused spe-
cifically on people above the age of 60.6–8 Our findings 
are generally in line with their results. For instance, an 
Australian study in men aged 69 and older found a haz-
ard ratio of 1.70 (1.19 to 2.42) for a combined endpoint of 
stroke and myocardial infarction.6 A large Japanese 
study yielded relative cardiovascular mortality risks of 
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Fig 2 | Meta-analysis of risk advancement periods (RAP) for current smoking status and cardiovascular mortality
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1.41 (1.19 to 1.67) for male smokers and of 1.69 (1.32 to 
2.15) for women aged 65 to 79 years over 10 years of 
 follow-up.8 This study also observed a decline of the 
risk within a few years after smoking cessation, which 
is comparable with our findings. Only one previous 
study on the impact of smoking on cardiovascular out-
comes reported risk advancement periods in addition to 
traditional risk measures.7 This study from Germany 
used data from the ESTHER cohort, which is also 
included in this present work (albeit with a longer fol-
low-up time of 13 years and with older participants 
excluding those younger than 60). In the age group of 60 
to 74, a hazard ratio of 2.50 (1.74 to 3.61) for cardiovascu-
lar mortality and a corresponding risk advancement 
period estimate of 7.8 (4.3 to 11.3) years over 10 years of 
 follow-up were reported, which is somewhat higher 
than the estimates observed in this present work but the 
dose-response patterns are consistent.
Our results on the benefits of smoking cessation are 
particularly noteworthy because so far the impact of 
cessation on cardiovascular mortality and disease risks 
have rarely been studied in older adults. Even though 
the risk avoided by smoking cessation is greater the ear-
lier a smoker quits,3 our data show that smoking cessa-
tion was still associated with a substantial reduction of 
cardiovascular risks even in the oldest age groups. The 
hazard ratio of cardiovascular mortality was significantly 
reduced to 0.84 compared to continuing smokers already 
after five years since cessation. And within 20 years 
after smoking cessation, the excess risk compared to 
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Fig 3 | Cardiovascular mortality summary estimates (random effects model) of hazard ratios and risk advancement periods 
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never smokers reduced to an only slightly elevated haz-
ard ratio of 1.15. Thus, and in contrast to common 
misperceptions that older adult smokers might be too 
old to benefit from quitting, our findings indicate that 
smoking cessation should be encouraged at any age.
The excess risk in current and former smokers for 
adverse cardiovascular outcomes was still substantial 
in those aged 70 and older, but the relative association 
was weaker compared with those aged 60 to 69. This is 
in line with findings from a British case-control study 
showing that the association of smoking and myocar-
dial infarction weakens with every 10 year age group.11 
One explanation for this phenomenon could be the 
“depletion of susceptibles” effect:25 owing to their 
increased mortality risks, a depletion of the number of 
higher risk smokers occurs while the healthier or lower 
risk people remain, leading to an attenuation of associ-
ations. Competing risks in smokers owing to increased 
hazards for other serious diseases caused by smoking 
might also play a role.26 But even though the impact of 
smoking appears to be somewhat weaker at older ages 
in relative terms, it may still be as large or even larger in 
absolute terms given the strong rise of incidence and 
mortality from cardiovascular diseases with age.
Richard Peto has coined the phrase “If women smoke 
like men, they die like men” when commenting on the 
similarly high smoking related all cause mortality risks in 
women compared with men.27 For adverse cardiovascular 
outcomes, our findings indicate that female smokers 
above the age of 60 have even somewhat higher relative 
risks than men. This is in accordance with findings from 
a recent meta-analysis of 75 prospective cohort studies 
that revealed that women had a 25% higher risk for cor-
onary heart disease conferred by smoking compared 
with men.28 A similar meta-analysis on stroke pooled 
results from 25 Western cohorts and found that women 
had a 10% higher risk for stroke compared with men.29 
Whether such differences are result of biological differ-
ences or other mechanisms is unclear,28 29 but the 
female to male ratio of the smoking related hazard 
ratios in our study were of comparable magnitude for 
all cardiovascular outcomes.
limitations and strengths
Even though the risk estimates appear remarkably con-
sistent across the single cohorts, I2 and Q statistics of 
our meta-analyses suggest high and significant hetero-
geneity. The I2 describes the percentage of total variabil-
ity across studies that is due to heterogeneity rather 
than chance,21 which for instance was 82.3% (and 
68.7%) in the meta-analyses on the association of cur-
rent (and former) smoking with cardiovascular mortal-
ity. Apart from differences in study design, the variation 
in age distributions between cohorts could be one rea-
son for the large heterogeneity. Indeed, age stratifica-
tion reduced the I2 measure substantially to 40.8% for 
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the current smoking models (40.0% for the former 
smoking models) for the age group 60 to 69, and to 
65.6% (52.9%) for the age group 70 and older. NIH-AARP 
also contributed to heterogeneity between study results 
owing to its high statistical power that resulted in pre-
cise estimates with narrow confidence intervals. This 
reduced the extent of overlap in confidence intervals 
across studies, on which the I2 metric strongly depends, 
and thus inflated its value.30 Repeating the meta-analy-
ses after exclusion of NIH-AARP accordingly led to sub-
stantially lower I2 values (56.2% and 58.6%) and shifted 
the summary estimates of the fixed effect model (for 
example, hazard ratio 2.02 (1.82 to 2.25) for current 
smoking and cardiovascular mortality, and 1.35 (1.23 to 
1.49) for former smoking) towards the results of the 
 random effects model. Acknowledging the statistical 
heterogeneity across the included cohort studies, we 
decided to follow a conservative approach and to report 
summary estimates of the random effects models as 
main results.
Some further limitations of our study need to be con-
sidered. Although all data were harmonised based on 
consented harmonisation rules, the data from the dif-
ferent cohort studies are still not perfectly comparable 
owing to differences in study design and data collection 
procedures, and to inconsistencies in definitions of 
variables. In addition, some cohorts did not have all 
variables available and models were thus fitted without 
these; however, sensitivity analyses by excluding these 
cohorts from the models did not change the summary 
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estimates to any meaningful extent. Irrespective of such 
drawbacks, our approach of conducting a meta-analy-
sis with individual participant data from different 
cohort studies being harmonised and uniformly anal-
ysed can be presumed to be more valid compared to a 
traditional meta-analysis of published studies.31 A few 
other limitations might have contributed to an underes-
timation of the true associations of smoking with car-
diovascular outcomes. Firstly, since we included only 
participants aged 60 and older in our study, heavier and 
long term smokers are probably under-represented in 
our sample owing to their increased mortality risks. 
Such a differential mortality bias would have led to an 
underestimation of risks for smokers. Secondly, we can-
not rule out bias due to social desirability or imperfect 
recall, which could have led to under-reporting and 
thus to misclassification of current or former smokers to 
the never smoker category and thus to an underestima-
tion of risk estimates. Thirdly, smoking was assessed at 
baseline only and repeated measurements of smoking 
behaviour over follow-up were not available. While 
smoking initiation is quite unlikely in older never smok-
ers, smoking cessation in baseline smokers and 
relapses in former smokers are likely, leading to an 
underestimation of the effects of smoking and the ben-
efits of quitting.32 The true associations of smoking and 
smoking cessation with cardiovascular outcomes are 
therefore probably stronger than observed in our study.
Particular strengths of our study are the focus on a 
previously understudied population, the inclusion of a 
large number of cohorts that cover a wide geographical 
area and the resulting broad generalisability of our 
results to older populations. Owing to the large sample 
size and accordingly high statistical power, we were fur-
ther able to provide quite precise estimates for both 
hazard ratios and risk advancement periods.
implications and conclusions
Even though comparably high quit success rates can be 
achieved, studies suggest that older smokers are less 
likely to receive smoking cessation support than 
younger smokers.33–35 Hence, our findings on the haz-
ards of smoking and the benefits of quitting in older 
ages have important public health implications. Despite 
the attenuation of the relative risks with age, smoking 
cessation interventions in older adults could probably 
achieve even greater absolute reductions in adverse car-
diovascular events than in younger or middle aged pop-
ulations given the trends of population ageing in higher 
income countries and the higher incidence of cardio-
vascular events and mortality in older age.5 This tre-
mendous potential for cardiovascular disease 
prevention will remain largely untapped unless tobacco 
prevention efforts in older people are intensified. Risk 
communication is especially crucial in promoting 
smoking cessation and risk advancement periods could 
be easier to grasp for the general public than other epi-
demiological risk measures such as relative risks or 
years of life lost.13 14 In this study, we provided risk 
advancement period estimates for the association 
between smoking related variables and cardiovascular 
mortality. For example, we found a risk advancement 
period of 5.5 for cardiovascular mortality in current 
smokers in reference to never smokers, which denotes 
that death from cardiovascular disease is advanced by 
5.5 years in the average current smoker above the age of 
60 compared with the average never smoker of the same 
age. A risk advancement period of −1.34 for former 
smokers who stopped smoking 5 to 9 years ago (in refer-
ence to current smokers) denotes that these former 
smokers already “gained” 1.34 years through quitting 
and abstaining from smoking for at least five years. 
While we can only hypothesise that risk advancement 
periods might be a useful tool to convey the risks of 
smoking and the benefits of smoking cessation to smok-
ers, we strongly encourage the realisation of experi-
mental or intervention studies to evaluate the utility of 
risk advancement periods in the context of clinical or 
community programmes—for instance, by using the 
estimates that we provided in this study.
To conclude, our results corroborate and expand 
existing evidence that smoking is a strong independent 
risk factor of cardiovascular events and mortality even 
at older age, advancing cardiovascular mortality by 
more than five years. Importantly, our study reveals that 
even in older adults, smoking cessation is beneficial in 
reducing the excess risk caused by smoking. Given the 
current trends in demographic ageing, smoking cessa-
tion programmes should also focus on older people to 
curb the burden of smoking associated disease and 
mortality.
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